Back by popular demand, our live, interactive HGMD Professional sessions are designed to help you master the skills needed to navigate and use the industry-leading database like an expert. This virtual training session will show you how to effectively leverage the extensive features and functionalities of HGMD Professional compared to its public counterpart.
Attendees will learn how to:
Learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab rapidly identify pathogenic variants, improve diagnostic yields, and significantly reduce test turnaround time for hereditary diseases. Attendees will receive a demonstration of QCI Interpret’s unique capabilities and advanced features for germline variant interpretation with example workflows for carrier screening and whole-exome sequencing panels. Key highlights will include how your lab can expedite variant interpretation by leveraging the most extensive, manually curated knowledge base, dynamically compute pathogenicity based on ACMG guidelines for every variant with full transparency, and leverage QCI Interpret’s proprietary augmented molecular intelligence approach to literature curation and variant classification to streamline your interpretation workflow.
In this webinar, attendees will:
Speaker:
Elias Hage, PhD, is the Associate Director of Global Product Management for Hereditary Disease and Oncology Applications at QIAGEN Digital Insights (QDI). In this role, he oversees the development, management, and optimization of QDI software, databases and services for genomic analysis and interpretation of hereditary disease and oncology cases. Prior to joining QDI, Dr. Hage served as a Global Product Manager at Agilent Technologies, where he managed the Genomics division flagship SaaS application (Alissa Interpret) and supported its usage globally in both research and IVD settings. Dr. Hage obtained his Ph.D. in virology and genomics from Hannover Medical School in Belgium.
This year at the 2024 Association for Molecular Pathology (AMP) Annual Meeting, QIAGEN will showcase our barrier-breaking Sample to Insight Oncology solution. Combining targeted DNA and multimodal pan-cancer panels, one of the fastest and cheapest secondary analysis solutions in the market, and industry-leading variant interpretation and reporting software trusted to analyze and interpret over 4 million NGS patient test cases worldwide, our Sample to Insight Oncology solution is revolutionizing precision oncology testing.
Lean more and schedule a VIP meeting with our experts at AMP 2024 here.
This year at the 2024 American Society of Human Genetics (ASHG) Annual Meeting, QIAGEN will showcase our Sample to Insight solutions for human genetics and inherited disease applications. From digital PCR technologies and actionable exome panels to one of the fastest and cheapest secondary analysis solutions in the market and industry-leading variant interpretation and reporting software trusted to analyze and interpret over 4 million NGS patient test cases worldwide, our Sample to Insight solutions are revolutionizing genetic testing.
Learn more and schedule a VIP meeting with our experts at ASHG 2024 here.
This year at the 2024 Precision Medicine Forum Berlin, QIAGEN will showcase our barrier-breaking Sample to Insight Oncology solution. Combining targeted DNA and multimodal pan-cancer panels, one of the fastest and cheapest secondary analysis solutions in the market, and industry-leading variant interpretation and reporting software trusted to analyze and interpret over 4 million NGS patient test cases worldwide, our Sample to Insight Oncology solution is revolutionizing precision oncology testing.
Learn more and register here.
For US-based labs interested in learning more about QCI Interpret for Oncology, QIAGEN’s clinical decision support software for variant interpretation and reporting, we are hosting an exclusive, interactive virtual workshop where you can access and demo the software for free. Each attendee will be given a temporary license and a VCF file to run a case on the industry-leading software. Through a guided session, you will be able to see first-hand how QCI Interpret works, with full exploration of the software’s capabilities and features.
In this workshop, you will see how QCI Interpret:
• Dynamically computes pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in all cancer types with full transparency.
• Provides access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports.
• Effortlessly streamlines case reviews by automatically selecting reportable variants, along with tailored treatments and trials.
Only 40 spots available. Must apply by October 25, 2024.
This workshop is an exclusive event limited to a select number of participants. To register, you must provide a work email and be selected by QIAGEN to attend. The workshop will be hosted on a US server and no customer data will be involved.
Learn more and register here.
Industry leaders discuss how to improve the speed, precision and cost-effectiveness of clinical exome testing for newborn screening and rare and undiagnosed diseases
Clinical exome testing is revolutionizing the diagnosis of rare and inherited diseases. Its ability to quickly pinpoint the genetic causes of complex conditions has made it a critical component of personalized medicine, leading to earlier diagnoses, targeted treatments and improved patient outcomes. However, without the right strategies, databases and informatics tools, clinical exome testing remains inaccessible for many small to mid-sized laboratories.
The Third Annual Clinical Hereditary Disease Diagnostics Summit hosted by QIAGEN Digital Insights will examine the incredible opportunities—and challenges—of brining clinical exome testing in-house. Join industry leaders as they discuss how labs, regardless of size, budget and experience, can integrate exome testing into routine clinical care with transformative impact for providers and their patients.
Featured topics will include:
Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the identification of essential molecular aberrations for personalized therapies. By focusing only on a subset of genes, targeted NGS is not only a cost-effective solution, but can rapidly deliver insights into a tumor molecular profile.
To address this challenge, a clinical research team led by Dr. Michela Bulfoni at the Istituto di Anatomia Patologica designed custom NGS panels, named “Glioma” and “Routine Diagnostics”, targeting single nucleotide variations, insertions/deletions, fusions, and copy number variations of tumor-associated essential genes.
In this webinar, attendees will:
Understand the clinical utility of custom-designed NGS panels for accurate tumour diagnosis
Learn about the design and application of these NGS panels
Gain insights into the cost-effectiveness and high sensitivity of NGS panels in improving sample throughput
Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.
To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.
In this webinar, attendees will learn how QCI Secondary Analysis:
